Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 425-400-6 | CAS number: 179986-09-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 50
- Modified dose descriptor starting point:
- NOAEC
Acute/short term exposure
DNEL related information
Local effects
Acute/short term exposure
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.93 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
DNEL related information
Workers - Hazard for the eyes
Additional information - workers
Based on the available data, there is no need to classify the test substance under EU Annex VI of directive 67/548/EEC and CLP regulation (EC) 1272/2008.
No systemic/local hazard was identified in rodent studies after short-term exposure. A NOAEL of 14 mg/kg bw was defined in a 90-days repeated toxicity study (Notox 487736, 2008, combined with a one-generation reproductive toxicity study). The test substance was administered orally to male and female rats at dose levels of 14, 56 and 222 mg/kg bw. Liver and thyroidal changes (increase in organ weights and epithelial hypertrophy at histopathology) in the 56 and 222 mg/kg bw dose groups were observed. This NOAEL is supported by the results of a one-generation reproductive toxicity study (Notox 487736, 2008), where the same effects on liver and thyroid were observed as in the subchronic study. The substance belongs to the group of metilox esters that is known to cause secondary effects on rat thyroid functions via induction of liver metabolism. The DNEL is derived from the NOAEL for liver epithelial cell hypertrophy.
Point of departure
The starting point is a NOAEL of 14 mg/kg bw/day obtained from a subchronic oral study with rats (Notox 487736, 2008).
DNEL calculation – workers
In general, the derivation of DNEL is based on the above described NOAEL, which is modified as described in ECHA-guidance R.8 (2008).
Inhalation
Extrapolation from oral rat NOAEL to a corrected inhalatory NOAEL - Worker:
In order to adjust the NOAEL for inhalation as relevant exposure route, factors were applied to adjust human respiratory conditions as well as duration of exposure as advised in the ECHA-guidance R.8: Conversion of oral dose to corresponding air concentration: 1/0.38; Correction for respiratory volume under light activity: 6.7/10.
Corrected starting point (worker):
14 mg/kg bw/day x (1/0.38 m3/kg/d) x (6.7 m3 (8h) / 10 m3 (8h)) = 24.68 mg/m3
Derivation of inhalative DNEL - Worker
No experimental data with repeated dosage regimen for this administration route is available. Therefore, the inhalation route is covered by route-to-route extrapolation (oral to inhalation). Toxicokinetic considerations indicate that the substance will undergo initial metabolism via digestive enzymes in the bile. This results in low molecular weight substances that are easily absorbed. Therefore, the bioavailability of the substance by oral uptake is assumed to be at least as good as for the other routes of exposure. and an assessment factor of 1 was used for route-to-route extrapolation. The assessment factors were used as advised in ECHA-guidance R.8 (2008): allometric scaling: 1, remaining differences: 2.5, intraspecies factor for worker: 5; exposure duration (subchronic to chronic): 2.
Inhalative DNEL – Worker: 50 mg/m3 / (1x1x2.5x5x2) = 1 mg/m3
Dermal
No experimental data for this administration route with repeated dosage regimen is available. Therefore the dermal route is covered by route-to-route extrapolation (oral to dermal). As described in the toxicokinetic section, the oral rout of the exposure is most favourable for this substance and skin permeability of 80% of the components is considered to be very poor. A factor of 0.3 is introduced to take into account the poorly permeable fraction. An additional factor of 0.5 is applied because the components that are predominantly responsible for the effects upon ingestion are the ones that are predicted to be very poorly permeating. Further assessment factors were used as advised in ECHA-guidance R.8 (2008): correction for differences in metabolic rate (rat to human): 4, remaining differences: 2.5, intraspecies factor for worker: 5; exposure duration (sub-chronic to chronic): 2.
Dermal DNEL – Worker: 14 mg/kg bw/day / (1x4x2.5x5x2x0.3x0.5) = 0.93 mg/kg bw/day
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.09 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- NOAEC
Acute/short term exposure
DNEL related information
Local effects
Acute/short term exposure
- Hazard assessment conclusion:
- exposure based waiving
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.33 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
DNEL related information
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.05 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
DNEL related information
General Population - Hazard for the eyes
Additional information - General Population
Point of departure
The starting point is a NOAEL of 14 mg/kg bw/day obtained from a subchronic oral study with rats (Notox 487736, 2008), which is corrected for the differences in the experimental and human exposure conditions (7 days of exposure for the general population and 5 days in the animal study). According to the procedure recommended in ECHA-guidance R.8 (2008), a converted NOAEL of (14*(5/7))=10 mg/kg bw/day is then obtained.
DNEL calculation – general population
In general, the derivation of DNEL is based on the above described NOAEL, which is modified as described in ECHA-guidance R.8 (2008).
Oral
Derivation of oral DNEL – general population
A corrected NOAEL of 10 mg/kg bw was assessed. Overall assessment factors were applied as advised in ECHA-guidance R.8 (2008): correction for differences in metabolic rate (rat to humans): 4; remaining differences: 2.5, intraspecies factor for general population: 10; exposure duration: (sub-chronic to chronic): 2.
Oral DNEL – general population: 10 mg/kg bw/day / (4x2.5x10x2) = 0.05 mg/kg bw/day
Corrected starting point (general population):
10 mg/kg bw/day x 1/1.15 m3/kg /day = 8.70 mg/m3
Derivation of inhalative DNEL - general population
No experimental data with repeated dosage regimen for this administration route is available. Therefore, the inhalation route is covered by route-to-route extrapolation (oral to inhalation). Since, no data on toxicokinetics and no information on the molecular weight and log Pow are available for the test substance, a prediction concerning bioavailability can not be stated. Therefore, the bioavailability of the substance by oral uptake is assumed to be 50 %, and 100 % for inhalation (worst case assumption) and an assessment factor of 2 was used for route-to-route extrapolation. The assessment factors were used as advised in ECHA-guidance R.8; remaining differences: 2.5, intraspecies for general population: 10; exposure duration (sub-chronic to chronic): 2 Inhalative DNEL – general population: 8.70 mg/m3 / (2x2.5x10x2) = 0.09 mg/m3
Dermal
No animal data are available investigating the repeated dose toxicity of the test substance after dermal application. Therefore, the dermal route is covered by route-to-route extrapolation from oral to dermal. Since no data on bioavailability after dermal application are available, it is assumed that dermal absorption will not be higher than oral absorption and a default factor of 1 is introduced. Further assessment factors were used as advised in ECHA-guidance R.8 : correction for differences in metabolic rate (rat to human): 4, remaining differences 2.5; intraspecies factor for general population: 10; exposure duration (sub-chronic to chronic): 2. As described in the section of the worker DNEL, two factors of 0.3 (skin permeability) and 0.5 (permeating component) are introduced.
Dermal DNEL – general population:
10 mg/kg bw/day / (1x4x2.5x10x2x0.5x0.3) = 0.33 mg/kg bw/dayInformation on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.